Inhibition of platelet aggregation (Update 2019)

Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in diabetic patients. Inhibition of platelet aggregation can reduce the risk for acute ather...

Full description

Saved in:
Bibliographic Details
Published in:Wiener Klinische Wochenschrift 2019-05, Vol.131 (Suppl 1), p.139-140
Main Authors: Wascher, Thomas C, Saely, Christoph H
Format: Article
Language:ger
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in diabetic patients. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in diabetic patients according to current scientific evidence.
ISSN:1613-7671
DOI:10.1007/s00508-018-1437-6